…/2 because they include everything happening to the trial participant. Like the disease process itself causing some of them, as well as the ones that are random. It takes a little bit of digging to ferret out the ones to worry about and are statistically significant.…/2

…/3 as well as their significance and contribution to risk. I am a lukewarm enthusiast for this class of drugs. They do absolutely nothing to address the metabolic defects of the disease. Where there has been demonstrated benefit is in the treatment of concomitant CHF. Increased UTIs are given.